TP53 and acute myeloid leukemia: Thus, these data are in accordance with the results of Gasparian et al., who revealed CBL0137-mediated p53 activation and with the modern trend in AML chemotherapy to activate expression of tumor suppressors by epigenetic drugs [2,12].